OA11569A - Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. - Google Patents

Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. Download PDF

Info

Publication number
OA11569A
OA11569A OA1200000346A OA1200000346A OA11569A OA 11569 A OA11569 A OA 11569A OA 1200000346 A OA1200000346 A OA 1200000346A OA 1200000346 A OA1200000346 A OA 1200000346A OA 11569 A OA11569 A OA 11569A
Authority
OA
OAPI
Prior art keywords
oxo
pyridin
ethyl
phenyl
compound
Prior art date
Application number
OA1200000346A
Other languages
English (en)
Inventor
Hua Zhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of OA11569A publication Critical patent/OA11569A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
OA1200000346A 1998-06-16 1999-05-03 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty. OA11569A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8942498P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
OA11569A true OA11569A (en) 2004-07-01

Family

ID=22217565

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000346A OA11569A (en) 1998-06-16 1999-05-03 Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty.

Country Status (29)

Country Link
EP (1) EP1085867A1 (de)
JP (1) JP2002518328A (de)
KR (1) KR20010052817A (de)
CN (1) CN1305378A (de)
AP (1) AP9901581A0 (de)
AR (1) AR018868A1 (de)
AU (1) AU3342099A (de)
BG (1) BG105128A (de)
BR (1) BR9911357A (de)
CA (1) CA2335112A1 (de)
CO (1) CO5070586A1 (de)
EA (1) EA200001189A1 (de)
GT (1) GT199900083A (de)
HR (1) HRP20000857A2 (de)
HU (1) HUP0102395A2 (de)
ID (1) ID26726A (de)
IL (1) IL139587A0 (de)
IS (1) IS5727A (de)
MA (1) MA26648A1 (de)
NO (1) NO20006381D0 (de)
OA (1) OA11569A (de)
PA (1) PA8472101A1 (de)
PE (1) PE20000633A1 (de)
PL (1) PL345064A1 (de)
SK (1) SK18902000A3 (de)
TN (1) TNSN99118A1 (de)
UY (1) UY25557A1 (de)
WO (1) WO1999065488A1 (de)
ZA (1) ZA993973B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004306A3 (de) * 1998-08-06 2000-06-07 Pfizer Products Inc. Estrogen Agonisten/Antagonisten
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
BR0113626A (pt) 2000-08-30 2003-06-17 Pfizer Prod Inc Formulações de liberação sustentada para secretores de hormÈnio do crescimento
US7524866B2 (en) 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
ES2319785T3 (es) * 2001-11-29 2009-05-12 Gtx, Inc. Prevencion y tratamiento de osteoporosis inducida por privacion de androgenos.
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
EA200901077A1 (ru) 2007-02-09 2010-04-30 Транзим Фарма, Инк. Макроциклические модуляторы грелинового рецептора и их применение

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (uk) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)цис-6(s)-феніл-5(r)[4-(2-піролідин-1-ілетокси)феніл]-5,6,7,8-тетрагідронафталін-2-ол d-тартрат, спосіб його одержання, спосіб лікування захворювань, що піддаються лікуванню агоністами естрогену, та фармацевтична композиція
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis

Also Published As

Publication number Publication date
UY25557A1 (es) 2001-01-31
PA8472101A1 (es) 2000-09-29
ID26726A (id) 2001-02-01
EP1085867A1 (de) 2001-03-28
IS5727A (is) 2000-11-24
WO1999065488A1 (en) 1999-12-23
PL345064A1 (en) 2001-11-19
TNSN99118A1 (fr) 2005-11-10
EA200001189A1 (ru) 2001-06-25
JP2002518328A (ja) 2002-06-25
PE20000633A1 (es) 2000-07-26
BG105128A (en) 2001-11-30
BR9911357A (pt) 2001-03-13
HUP0102395A2 (hu) 2001-11-28
KR20010052817A (ko) 2001-06-25
AP9901581A0 (en) 1999-06-30
IL139587A0 (en) 2002-02-10
HRP20000857A2 (en) 2001-10-31
NO20006381L (no) 2000-12-14
CN1305378A (zh) 2001-07-25
MA26648A1 (fr) 2004-12-20
CA2335112A1 (en) 1999-12-23
AU3342099A (en) 2000-01-05
AR018868A1 (es) 2001-12-12
NO20006381D0 (no) 2000-12-14
ZA993973B (en) 2000-12-15
SK18902000A3 (sk) 2001-12-03
CO5070586A1 (es) 2001-08-28
GT199900083A (es) 2000-12-05

Similar Documents

Publication Publication Date Title
EP1414486B1 (de) Anwendung von glp-2 in verbindung mit einem anderen therapeutischen mittel in knochenkrankheiten
US7632813B2 (en) Bone densifying agent characterized by use of cathepsin K inhibitor with PTH
JP2003528135A (ja) 糖尿病のランゲルハンス島シグナリングの改善方法及びその防止方法
JPH11180926A (ja) 骨粗しょう症用化合物
JP2000514840A (ja) 成長ホルモン分泌促進物質としての置換ジペプチドの酒石酸塩
KR20140084303A (ko) 소아 담즙울체성 간 질환 치료용 담즙산 재순환 억제제
CN109922812A (zh) 减少与甲状腺相关的副作用的方法
HRP980356A2 (en) Prostaglandin agonists
US20050065133A1 (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist
US20050065180A1 (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and a growth hormone secretagogue
OA11569A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues(GHS) for treating musculoskeletal frailty.
OA11566A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone.
US20020002137A1 (en) Combination of growth hormone secretagogues and antidepressants
OA11505A (en) Therapeutic combinations of (selective) estrogen receptor modulators (SERM) and growth hormone secretagogues (GHS) for treating musculoskeletal frailty.
EP1490055A1 (de) Verwendung von selektiven ep4 rezeptor-agonisten zur behandlung von leberinsuffizienz, verlust der durchgängigkeit des ductus arteriosus, glaukom oder okularer hypertonie
CZ20004680A3 (cs) Terapeutické kombinace (selektivních) modulátorů estrogenního receptorů (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
US6284773B1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin E2
MXPA00012628A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
CZ20004679A3 (cs) Terapeutické kombinace (selektivních) modulátorů estrogenního receptoru (ŠERM) a prostředků podporujících sekreci růstového hormonu (GHS) pro léčbu muskuloskeletární fragility
MXPA00012727A (en) Therapeutic combinations of (selective) estrogen receptor modulators (serm) and growth hormone secretagogues (ghs) for treating musculoskeletal frailty
MXPA00012728A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and parathyroid hormone
MXPA99005564A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2